000			03433cam a2200325 a 4500
003			EG-GiCUC
008			210919s2021 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.09.08.Ph.D.2021.Ah.C
100	0		_aAhmed Adel Mohamed Abdelazim
245	1	0	_aCancer chemoprevention by Metformin Hydrochloride compared to placebo in oral potentially malignant lesions : _bA randomized clinical trial (part I) / _cAhmed Adel Mohamed Abdelazim ; Supervised Fat{u2019}heya Mohamed Zahran , Gihane Gharib Madkor , Heba Ahmed Farrag
246	1	5	_aالوِقايَةٌ الكِيمْيائِيَّة من السرطان بواسطة هيدروكلوريد الميتفورمن مقارنة بالغُفْل في آفات الفم القابلة للتسرطن : _bدراسة إكلينيكيّة على عينات مختارة عشوائياً - الجزء الأول
260			_aCairo : _bAhmed Adel Mohamed Abdelazim , _c2021
300			_a201 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - Faculty of Oral and Dental Medicine - Department of Periodontology
520			_aAim: The aim of this study was to compare the effect of metformin hydrochloride on potentially malignant to placebo regarding its efficacy in regression or suppression of the progress into frank cancer. Methodology: This trial was a multicentre, triple{u00AD}blind, placebo{u00AD}controlled, randomized phase II trial. 40 non{u00AD}diabetic adult patients clinically and histologically diagnosed with OPMD were enrolled into the study. Eligible patients were randomly assigned (1:1) to receive oral met{u00AD} formin (500 mg daily) or identical placebo tablets by a stratified computer{u00AD}based randomization method for a duration of 3 months. All patients, clinicians, and outcome assessors were masked to drug allocation until the end of the trial. Recommended standard health and dental care were given to both groups.Clinical data, biopsies, immunohistochemical staining of cyclin D1, and RT{u00AD}qPCR quantification of tissue and salivary miRNA{u00AD}21 were performed for all groups at baseline and at three months point. Results: The current study showed that metformin was effective as a cancer chemopreven{u00AD} tive agent in controlling some of the molecular mechanisms that could lead to the the malignant transformation of OPMDs. Clinical lesion size, nuclear expression of cyclin D1, and tissue and salivary levels of cancer{u00AD}associated miRNA{u00AD}21 showed a statistically significant reduction in the metformin group compared to the placebo group. Cyclin D1 and miRNA{u00AD}21 correlated well to the degree of epithelial dysplasia, while toluidine blue color intensity was of limited value as a prognostic aid in OPMD. miRNA{u00AD}21 demonstrated a positive correlation between tissue and saliva levels, highlighting the emerging role of salivary transcriptomics in the field of OPMDs and oral cancer
530			_aIssued also as CD
653		4	_aCancer chemoprevention
653		4	_aMetformin Hydrochloride
653		4	_aPotentially malignant
700	0		_aFat{u2019}heya Mohamed Zahran , _eSupervisor
700	0		_aGihane Gharib Madkor , _eSupervisor
700	0		_aHeba Ahmed Farrag , _eSupervisor
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c82263 _d82263